New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
09:59 EDTOPKOPKO Health confirms orphan designation for longer-acting Factor VIIa-CTP
OPKO Health announced that the U.S. Food and Drug Administration has granted orphan drug designation to OPKO's longer-acting version of clotting Factor VIIa for the treatment of bleeding episodes in patients with hemophilia A or B with inhibitors to Factor VIII or Factor IX. Currently, Factor VIIa therapy is available only as an intravenous formulation, OPKO said. OPKO CEO Phil Frost said, "Expecting to initiate a Phase IIa trial with our IV formulation in hemophilia patients in late 2014, we believe that we are in a unique position to be first to market with a longer acting Factor VIIa product.
News For OPK From The Last 14 Days
Check below for free stories on OPK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
10:42 EDTOPKOPKO Health granted RAYALDEE patent from USPTO
Subscribe for More Information
July 11, 2014
12:19 EDTOPKOPKO Health spikes higher, levels to watch
Subscribe for More Information
12:16 EDTOPKOPKO Health spikes up after David Miller comments on insider purchases
Subscribe for More Information
05:57 EDTOPKStocks with implied volatility movement; OPK VIX
Subscribe for More Information
July 9, 2014
13:25 EDTOPKOPKO Health's VIIa-CTP receives positive opinion in Europe
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use